Screener
Zymeworks ZYME Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
FAQ
- What is Zymeworks's cash & equivalents?
- Zymeworks (ZYME) reported cash & equivalents of $179.41M in Q2 2026.
- How has Zymeworks's cash & equivalents changed year-over-year?
- Zymeworks's cash & equivalents increased by 82.6% year-over-year, from $98.25M to $179.41M.
- What is the long-term trend for Zymeworks's cash & equivalents?
- Over 5 years (2020 to 2025), Zymeworks's cash & equivalents has grown at a -29.8% compound annual growth rate (CAGR), from $242.04M to $41.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Zymeworks's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude